



HAL
open science

Non-canonical nuclear function of glutaminase cooperates with Wnt signaling to drive EMT during neural crest development

Nioosha Nekooie Marnany, Alwyn Dady, Frédéric Relaix, Roberto Motterlini, Roberta Foresti, Sylvie Dufour, Jean-Loup Duband

► **To cite this version:**

Nioosha Nekooie Marnany, Alwyn Dady, Frédéric Relaix, Roberto Motterlini, Roberta Foresti, et al.. Non-canonical nuclear function of glutaminase cooperates with Wnt signaling to drive EMT during neural crest development. 2024. hal-04764469

HAL Id: hal-04764469

<https://hal.science/hal-04764469v1>

Preprint submitted on 4 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Submitted version

Non-canonical nuclear function of glutaminase cooperates with Wnt signaling to drive EMT during neural crest development

Nioosha Nekooie Marnany^{1*#}, Alwyn Dady², Frédéric Relaix¹, Roberto Motterlini¹, Roberta Foresti¹, Sylvie Dufour^{1*}, and Jean-Loup Duband^{1*}

¹ Institut Mondor de Recherches Biomédicales, INSERM, Université Paris-Est Créteil, 94000 Créteil, France

² Laboratoire Gly-CRRET, Université Paris-Est Créteil, 94000 Créteil, France

* Authors for correspondence: jean-loup.duband@inserm.fr, sylvie.dufour@inserm.fr, and nioosha.nekooie@bio.ens.psl.eu

Present address: Institut de Biologie de l'Ecole Normale Supérieure, 75005 Paris, France

Running title: Nuclear glutaminase and neural crest EMT

Keywords: neural crest, delamination, EMT, glutamine, glutaminase (GLS), Wnt signaling

This manuscript contains 8 figures and 2 extended data figures.

29 **ABSTRACT**

30 Metabolic reprogramming has been linked to epithelial-to-mesenchymal transition (EMT) in cancer cells,
31 but how it influences EMT in normal cells remains largely unknown. Here we explored how metabolism
32 impacts delamination and migration of avian trunk neural crest cells, an important stem cell population
33 of the vertebrate embryo. We report that delamination exhibits a quiescent metabolic phenotype
34 whereas migration is characterized by OXPHOS-driven metabolism coupled to distinct expression of
35 metabolic, EMT and developmental genes. While glucose and glutamine are required for delamination
36 and migration, we uncover a novel role for glutamine and its catabolizing enzyme glutaminase in
37 delamination. Specifically, glutamine is required for nuclear translocation of glutaminase, which
38 interacts and cooperates with Wnt signaling to regulate EMT gene expression and cell cycle during
39 delamination. Our data indicate that similarly to cancer cells, embryonic cells engage metabolic enzymes
40 for non-canonical signaling functions to connect metabolism with EMT.

41

42 INTRODUCTION

43 Epithelium-to-mesenchyme transition (EMT) refers to the cellular program by which, through diverse
44 scenarios, epithelial cells lose their compact, ordered organization to become individual, migrating cells.
45 This process plays crucial roles during embryogenesis, morphogenesis, and tissue repair, but it can also
46 adversely cause organ fibrosis and promote cancer progression and metastasis [1]. EMT is context
47 dependent and triggered by numerous inducers, whose signaling cascades all converge to the Snail, Zeb
48 and Twist families of transcription factors (EMT-TFs) which control expression of genes for adhesion,
49 polarity and cytoskeleton molecules [2].

50 Because it establishes a direct link between the environment and gene networks, cellular
51 metabolism plays a key role in the unfolding of cell fate and function during EMT. Numerous studies
52 uncovered the mutual relationships between EMT and metabolism, and the molecular mechanisms
53 implicated are being unraveled in cancer cells [3-6]. Metabolic reprogramming occurs often as a
54 consequence of EMT during tumorigenesis, enabling cells to adapt to environmental changes. Thus, EMT
55 inducers can alter the cellular metabolic activity [7] and EMT-TFs can modify expression of metabolic
56 genes, profoundly affecting the glycolytic flux, oxygen consumption, or rewiring glycolysis to the pentose
57 phosphate (PP) pathway [8, 9]. Conversely, changes in the metabolic activity of cancer cells favor EMT. A
58 well-described example of this phenomenon is the hypoxia found in carcinoma that promotes anaerobic
59 glycolysis and activates the hypoxic-inducible factor 1, a potent regulator of EMT-TFs [10, 11]. Another
60 well-known metabolic process causing EMT in tumor cells is the Warburg effect in which energy derives
61 mainly from aerobic glycolysis and less from mitochondrial oxidative phosphorylation (OXPHOS) [12, 13].
62 The mechanisms by which metabolic activity induces EMT in cancer cells are extremely diverse. They
63 may rely on the accumulation of metabolites generated in mitochondria through the tricarboxylic acids
64 (TCA) cycle, which serve as cofactors or substrates of histone modifiers involved in epigenetic
65 regulations [14]. Alternatively, EMT can result from non-canonical functions of glycolytic enzymes, either
66 through their release into the microenvironment where they act as autocrine factors inducing EMT-TFs
67 or via their translocation into the nucleus where they exert a transcriptional regulatory activity [15-17].
68 However, the diverse molecular processes capable of inducing EMT along with the intrinsic
69 heterogeneity of tumor cells make it difficult to decipher which metabolic events are decisive in EMT [6].
70 Moreover, most metabolic alterations found in cancer cells result from extensive genomic alterations
71 and mitochondrial dysfunctions. Hence the need to investigate those mechanisms in normal cells that
72 undergo EMT in a predictable stereotyped fashion.

73 Neural crest cells (NCCs) of the vertebrate embryo represent a powerful model system to tackle
74 this question [18, 19]. Delamination, an EMT-related process, constitutes the founding event of this
75 stem cell population originating from the neural tube (NT), allowing the release of nascent NCCs from
76 their niche into the surroundings where they undergo migration and disperse away until differentiation
77 [20-22]. Owing to this process, NCCs give rise to a wide array of cell types throughout the body, from
78 cephalic skeletal tissues to melanocytes and peripheral neurons and glia. Recent studies provided
79 evidence that glucose metabolism plays an important role in NCC delamination and migration. In a
80 similar fashion to cancer cells, NCCs at cranial levels rely primarily on aerobic glycolysis to undergo EMT
81 with Yap/Tead signaling serving as the intermediate between glycolysis and activation of EMT-TFs [23].
82 Unlike their cranial counterparts, trunk NCCs display mitochondrial-dependent glucose oxidation and
83 mobilize several metabolic pathways downstream glucose uptake to execute their developmental
84 program [24]. Interestingly, trunk and cranial NCC delamination events are intrinsically different in their
85 kinetics, cellular processes, and in the molecular players recruited [20, 25, 26], thus raising the intriguing
86 question that metabolic activity might determine the scenario by which cells undergo EMT.

87 Here, using *in vivo* and *in vitro* strategies, we explored how metabolism drives transition from
88 delamination to migration in trunk NCCs. We report that delamination and migration differ in their
89 metabolic requirements in relation with the developmental gene networks involved. We show that
90 beside glucose, glutamine is required for NCC EMT and that glutaminase (GLS), the enzyme that
91 catalyzes glutamine transformation into glutamate, plays a major role in this process. Strikingly, GLS
92 function in delamination is independent of its enzymatic activity and is instead related to its nuclear
93 translocation, suggesting a non-canonical gene regulatory function. In fact we find that GLS cooperates
94 with β -catenin, a major player of Wnt signaling, to control expression of EMT-TFs and cell cycle during
95 NCC delamination. Thus, our data indicate that embryonic cells share similar molecular processes with
96 cancer cells, connecting metabolic events with gene regulation during EMT.

97

98 RESULTS

99 To examine the metabolic processes involved in trunk NCC delamination at the transition between their
100 pre-migratory and migratory states, we used the avian embryo, a model in which the spatiotemporal
101 features of delamination have been precisely mapped and characterized [27, 28]. Delaminating and
102 migrating NCCs can be discriminated using specific markers. Expressions of the EMT-TFs *Snail-2* and
103 *Foxd-3* peak at onset of EMT in synchrony with downregulation of the cell adhesion molecule *Cadherin-*
104 *6B*; these markers gradually decline at initiation of migration, while expression of *Sox-10*, a marker of

105 migration, increases (Fig. 1A; Extended data Fig.1A) [29-32]. In the thoracic region, delamination of the
106 NCC population occurs over a 15-h period from stage 12 of Hamburger and Hamilton (HH12; [33]) up to
107 stage 15. At HH12, pre-migratory NCCs express EMT markers and are about to undergo delamination. At
108 HH13, delamination culminates and, at stage HH14-15, while delamination is still underway, the already-
109 delaminated NCCs start migrating (Fig. 1A; Extended data Fig.1A). NCC delamination can be investigated
110 experimentally *in vivo* [34] and can be mimicked *in vitro* under defined cell culture conditions [35].
111 Therefore, this system allows to analyze the process of delamination and its switch to migration and to
112 decipher the individual and collective behaviors of NCCs, thereby providing a comprehensive
113 spatiotemporal survey of the underlying metabolic events.

114

115 **NCC transition from delamination to migration is coupled to a metabolic switch**

116 To study the bioenergetics profile of NT explants from embryos at stages encompassing the
117 delamination process from HH12-13 to HH14-15, we measured at the onset of culture oxygen
118 consumption rate (OCR) and extracellular acidification rate (ECAR) as readouts of mitochondrial
119 respiration and glycolysis, using a Seahorse XF analyzer. For this aim, we optimized the methodological
120 approach to individual NT explants for each measurement (Extended data Fig.1B), and we analyzed a
121 large collection of samples (nearly 250) for greater accuracy and to circumvent the intrinsic variability in
122 development progression among embryos.

123 Intriguingly, we consistently observed two subsets of explants with distinct metabolic states, a
124 major one (70%) with an “OXPHOS-driven profile” characterized by high OCR, low ECAR and a high
125 OCR/ECAR ratio, and a minor one (30%) with a “metabolically-quiescent profile” characterized by low
126 OCR, low ECAR, and a low OCR/ECAR ratio (Fig. 1B,C). Using mitochondrial stress assays combined with
127 measurements of intracellular ATP, we found that mitochondrial respiration was greater in explants with
128 OXPHOS profile than in quiescent ones (Fig. 1D,E) and largely contributed to energy production (Fig.
129 1F,G). To determine whether these two metabolic profiles might be linked with NCC development, we
130 assessed the cellular and molecular features of NCCs in the explants after metabolic profiling. Explants
131 with an OXPHOS profile had a significantly greater capacity to produce large NCC outgrowths after 3 h of
132 culture, exhibiting a higher number of migrating cells and stronger expression of the migration marker
133 *Sox10* compared to the quiescent group (Fig. 1H-J). This suggests that explants with an OXPHOS profile
134 may be at a more advanced development state compared to quiescent cells. We therefore performed a
135 bioenergetics survey of individual explants over time in culture during the passage from delamination to
136 migration, which occurs during the first day of culture. We found that explants exhibiting a quiescent

137 profile at 3 h shifted to an OXPHOS profile after 20 h (Fig. 1K), while those with an OXPHOS profile at the
138 beginning maintained the same metabolic activity later on, as reported previously [24]. This explains the
139 metabolic heterogeneity observed in explants at 3 hours of culture. To further establish a
140 correspondence between the stage of NCC development and their metabolic activity, we focused on
141 embryos at stages covering either initiation (HH12-13) or termination (HH14-15) of delamination. The
142 proportion of the metabolic profiles varied significantly between the developmental stages. Most
143 explants at HH12-13 exhibited quiescent profiles while at HH14-15 a great majority of them displayed
144 OXPHOS profiles (Fig. 1L). In addition, NTs from HH12-13 embryos cultured *in vitro* for 3 h produced
145 fewer migrating NCCs than those from HH14-15 embryos (Fig. 1M).

146 Collectively, these data establish that the metabolic activity of NCCs is rewired from quiescence
147 to active mitochondrial respiration at the transition phase between delamination and migration (Fig.
148 1N). Thus, metabolic profiling is instrumental to discriminate reliably NT explants at delamination and
149 migration and investigate the molecular processes underlying the switch between the two stages.

150

151 **A change in glucose utilization accompanies NCC transition from delamination to migration**

152 Metabolic switch is often related to changes in metabolite demand and utilization. To explore which
153 metabolic programs are rewired during transition from delamination to migration, we focused first on
154 glucose metabolism, as it is a main energy supplier. We previously demonstrated that glucose is
155 required for trunk NCC development and that genes of several glycolytic enzymes are expressed in the
156 embryo at the time of migration [24]. Here, after metabolic profiling of NT explants *in vitro*, we
157 compared the mRNA levels at delamination and migration of the glucose transporter type-1
158 (*SLC2A1/GLUT-1*) and the enzymes phosphofructokinase-P (*PFK*), lactate dehydrogenase (*LDH*), and
159 pyruvate dehydrogenase complex (*PDH*) (Fig. 2A). To demonstrate the relevance of our approach with
160 the *in vivo* situation, data were compared with those obtained from extracts of the brachial region of
161 embryos at HH12-13 and HH14 (see procedure Extended data Fig.1C). Consistent with a greater energy
162 production, we found that except *LDH*, glycolytic enzymes were upregulated at migration compared
163 with delamination (Fig. 2B).

164 Next, we analyzed the effect of pharmacological inhibitors of glycolysis and OXPHOS, namely 2-
165 deoxyglucose (2-DG) and oligomycin (Fig. 2A), on the metabolic activity of NT explants, by recording OCR
166 and ECAR in individual explants and by measuring ATP levels. In explants at delamination, we observed
167 that oligomycin decreased OCR and reduced ATP levels, while 2-DG did not affect OCR but decreased
168 ATP (Fig. 2C,D). In contrast, consistent with our previous data [24], explants at migration exhibited a

169 drastic decrease in OCR and ATP with 2-DG and oligomycin (Fig. 2C,D). This indicates that during
170 delamination, rather than fueling glycolysis and OXPHOS, glucose might be utilized by alternative routes,
171 such as the PP pathway, while during migration, NCCs use glucose oxidation and mitochondrial
172 respiration as the main route for energy production. Consistent with this assumption, expression of the
173 gene for the phosphoribosyl-pyrophosphate synthase (PRPS), a key enzyme of purines and pyrimidines
174 synthesis in the PP pathway, was higher at delamination than migration phase (Fig. 2B). We therefore
175 evaluated the effect of the PP pathway inhibitor 6-aminonicotinamide (6-AN) (Fig. 2A) on NCC
176 metabolic activity. We found that in explants at delamination 6-AN had no impact on OCR but increased
177 ECAR and ATP (Fig. 2C-E), suggesting that blocking the PP pathway re-diverts glucose towards glycolysis
178 and lactate production. In contrast, in explants at the migration stage, 6-AN treatment changed neither
179 the metabolic profile nor ATP levels (Fig. 2C-E). We next quantified the mRNA expression of enzymes of
180 glucose metabolism in embryos at the time of NCC delamination and migration after *in ovo* injection of
181 6-AN (see procedure Extended data Fig.1D). We found that, at delamination 6-AN caused a significant
182 reduction in *PRPS* expression and an increase in *LDH* with no effect on *PFK*, while no significant changes
183 in these genes were detected during the migration phase (Fig. 2F). Altogether, these findings support a
184 change in glucose utilization during NCC transition from delamination to migration.

185

186 **Glutamine metabolism is required for NCC delamination and migration**

187 Because a metabolic switch may depend also on the type of metabolite used, we considered other
188 metabolic pathways that may accompany NCC transition from delamination to migration. We focused
189 on glutamine, a major contributor to macromolecules and ATP production known to cooperate with
190 glucose in cancer cells [36]. First, we explored the expression patterns of key enzymes involved in
191 glutamine metabolism (Fig. 2A) in the trunk of avian embryos, by *in situ* hybridization on whole mount
192 embryos and on sections. mRNAs for *SNAT-2*, encoding one of the glutamine transporters in neural cells,
193 glutaminase (*GLS*) and glutamate dehydrogenase (*GDH*) were all widely expressed at delamination and
194 migration (Fig. 3A). At the tissue level, mRNAs were distributed throughout the NT and were also
195 detectable in pre-migratory, delaminating and early-migrating NCCs (Fig. 3B). We also compared the
196 expression levels of these enzymes in metabolically profiled explants cultured *in vitro* as well as in
197 embryo extracts at HH12-13 and HH14. We found that *SNAT-2*, *GLS* and *GLUL* expressions remained
198 constant throughout NCC progression from delamination to migration, while *GDH*, encoding the enzyme
199 involved in glutamate conversion into α -ketoglutarate, was increased at migration (Fig. 3C). These data

200 indicate that glutamine metabolism is active during both delamination and migration and suggest that,
201 like for glucose, a change in glutamine utilization occurs during transition between the two stages.

202 To assess the implication of glutamine metabolism in delamination and migration, we used the
203 *in vivo* loss-of-function strategy (Extended data Fig.1D). DON, a glutamine analog that blocks all
204 metabolic routes downstream of glutamine uptake (Fig. 2A), was injected in the caudal region of HH12
205 embryos. Analyses by qRT-PCR of the embryos 5 h following injection revealed a robust repression of
206 *Foxd-3* and *Sox-10* and a more moderate decrease of *Snail-2* (Fig. 3D). Accordingly, DON strongly
207 decreased NCC delamination and caused migration defects after 24 h, as assessed by the alteration of
208 *Sox-10* pattern in the lower trunk (Fig. 3E). Spatiotemporal analyses of NCC distribution showed that
209 cells were missing at the top of the NT in the caudal trunk and were less numerous and trapped dorsally
210 instead of migrating ventrally in the mid-trunk (Fig. 3F). Therefore, consistent with the expression of
211 glutamine enzymes throughout NCC delamination and migration, these results establish that glutamine
212 is required for both events to occur.

213 In order to corroborate the role of glutamine, we analyzed the cellular and molecular responses
214 of NT explants confronted *in vitro* with medium depleted of glutamine. We found that, similarly to DON
215 effect, glutamine deprivation strongly impacted the numbers of NCCs (Fig. 3G) and of Snail-2-positive
216 cells (Fig. 3H) and the expression of EMT-TFs (Fig. 3I). The absence of glutamine also reduced the
217 expression of *Sox-10* (Fig. 3I), the outward expansion of the NCC population (Fig. 3J) and individual cell
218 velocity (Fig. 3K). Interestingly, *GLUL*, encoding glutamine synthetase that converts glutamate into
219 glutamine, was upregulated possibly due to a feedback adaptation (Fig. 3L). We also found by metabolic
220 profiling that none of the NT explants displayed a quiescent profile typical of the delamination stage.
221 Rather, despite a reduced capacity to undergo delamination and migration, the explants possessed an
222 OXPHOS profile, mitochondrial functions, and ATP levels (Extended data Fig.2A-E) similar to those
223 observed in NTs at migration (compare with Fig. 1B,C,E-G). Thus, it appears that glucose oxidation and
224 mitochondrial respiration cannot compensate for the lack of glutamine, despite their robust capacity to
225 provide energy. This result indicates that glutamine likely contributes to delamination and migration
226 independently of energy production, suggesting the intriguing possibility that metabolic quiescence
227 during delamination is related to glutamine metabolism.

228

229 **Glutaminase exhibits a non-canonical function during NCC delamination**

230 To investigate how glutamine metabolism drives NCC delamination and migration, we targeted GLS, the
231 enzyme involved in glutamine-to-glutamate conversion. To this aim, we injected *in ovo* prior to

232 delamination at HH12 either the CB-839 compound, to block GLS activity (Fig. 2A) [37], or siRNAs to *GLS*
233 to repress its expression. Both strategies resulted in severe alterations of NCC delamination and
234 migration. Specifically, CB-839 significantly decreased *Foxd-3* and *Sox-10* mRNA levels (Fig. 4A), and
235 strongly reduced the expression domain of *Foxd-3* in the dorsal NT at 5 h during delamination and of
236 *Sox-10* at 24 h during migration (Fig. 4B,C). In addition, when applied onto NT explants in culture, CB-839
237 strongly diminished the numbers of NCCs and of Snail-2-expressing cells (Fig. 4D). Silencing *GLS* by
238 siRNAs caused a dose-dependent reduction of its expression with an almost complete deletion at the
239 highest dose (Fig. 4E). As observed with CB-839, *GLS* extinction repressed *Snail-2*, *Foxd-3* and *Sox-10*
240 expression (Fig. 4E), accompanied by a severe reduction of NCC delamination and migration (Fig. 4F,G).

241 To further understand the role of GLS in these events, we compared the metabolic, cellular, and
242 molecular responses of NT explants treated with CB-839 at delamination and migration phases. We first
243 characterized the metabolic profiles of individual explants before and after addition of CB-839, and we
244 quantified the expression of NCC markers and glutamine metabolism enzymes, along with ATP levels.
245 Interestingly, GLS inhibition at delamination caused a significant decrease in *Snail-2*, *Foxd-3* and *Sox-10*
246 expressions, but had no impact on OCR, ECAR and ATP levels (Fig. 5A,B,D). Conversely, at migration, CB-
247 839 failed to alter the expression of NCC markers, but it decreased OCR and ATP production (Fig.
248 5A,B,D). Moreover, CB-839 differentially affected the expression of glutamine enzymes during
249 delamination and migration (Fig. 5C). Notably, *GLUL* expression was reduced during delamination but
250 not during migration. These data suggest that GLS may play distinct roles during delamination and
251 migration.

252 Because GLS converts glutamine to glutamate, we measured the intracellular concentration of
253 glutamine and glutamate in NT explants at delamination and migration after metabolic profiling.
254 Strikingly, the concentrations of glutamine and glutamate were lower at delamination than at migration
255 (Fig. 5E,F). Moreover, the concentration of glutamate in NCCs was severely decreased by CB-839 during
256 migration but not during delamination (Fig. 5E,F). These data suggest that GLS enzymatic activity is low
257 during delamination, but is enhanced during migration, matching the high levels of ATP. To address
258 whether glutamate derived from GLS activity could affect the responses of NT explants, we performed
259 experiments adding glutamate to the culture medium in place of glutamine to bypass GLS enzymatic
260 activity. We found that the number of NCCs, the proportion of Snail-2-expressing cells, and the levels of
261 *Snail-2*, *Foxd-3* and *Sox-10* mRNAs in the presence of glutamate were lower than those measured in the
262 presence of glutamine, indicating that glutamate cannot compensate for the negative impact of
263 glutamine deprivation (Fig. 5G,H; compare with Fig. 3G-I). Likewise, *in ovo* injection of glutamate

264 together with siRNAs to *GLS* in embryos failed to restore the normal NCC delamination and migration
265 patterns (Fig. 5I). Notably, glutamate restored NCC metabolic properties. Indeed, while only an OXPHOS
266 profile was observed in absence of glutamine (Fig. S2A,B), in the presence of glutamate, the NT explants
267 exhibited the two classical OXPHOS and quiescent profiles with characteristics similar to those observed
268 in the presence of glutamine (Fig. 5J-L; compare with Fig. 1B-F). In addition, in glutamate-containing
269 medium the expression of enzymes of glutamine metabolism was altered, with a downregulation of *GLS*
270 and *GLUL*, and an increase in *GDH*, indicating that glutamate could activate downstream events fueling
271 the TCA cycle (Fig. 5M).

272 Altogether, our findings reveal that *GLS* contributes to the NCC delamination process
273 independently from its enzymatic activity, thereby raising the intriguing possibility that *GLS* exhibits a
274 non-canonical function. In contrast, at the migration stage, *GLS* enzymatic activity appears to be
275 important for maintaining ATP in association with active locomotion.

276

277 **Glutaminase translocates to the nucleus in delaminating NCCs**

278 To identify a potential non-canonical function of *GLS* during delamination, we compared its cellular
279 localization in delaminating and migrating NCCs. Intriguingly, we found that *GLS* was particularly
280 enriched in the nuclei of delaminating NCCs in addition to its normal cytoplasmic levels, whereas in
281 migrating cells *GLS* distributed throughout the cytoplasm without specific nuclear accumulation (Fig.
282 6A). Treatment of NT explants with CB-839 significantly decreased the proportion of delaminating NCCs
283 exhibiting nuclear *GLS* but had no effect on *GLS* localization in migrating cells (Fig. 6A,B). In addition, a
284 similar outcome was observed under glutamine-free conditions in the presence or absence of glutamate
285 (Fig. 6B), suggesting an essential role for glutamine in mediating the nuclear translocation of *GLS* in
286 delaminating NCCs.

287 We also investigated the cellular localization of *GLS* in trunk NCCs in embryos at delamination
288 stage. Confocal whole mount views of the NT dorsal region revealed the presence of *GLS* staining within
289 the nuclei of cells situated along the NT midline in the region of NCC delamination, while migratory cells
290 expressing Sox-10 and situated more laterally displayed low *GLS* nuclear staining (Fig. 6C). Analyses of
291 cross-sections through the NT confirmed the nuclear accumulation of *GLS* in NCCs at delamination but
292 not at migration (Fig. 6D). Interestingly, in areas where delamination occurs, nuclear localization of *GLS*
293 was not restricted to NCCs but was also detectable in more ventral NT cells. Finally, we analyzed *GLS*
294 localization in NCCs of embryos injected with siRNAs to silence *GLS* before delamination. In addition to
295 repressing NCC delamination and expression of EMT-TFs (Fig. 4E-G), *GLS* ablation caused the near

296 disappearance of GLS staining in the cytoplasm and nuclei of NCCs, contrary to control siRNAs, which did
297 not affect GLS expression and intracellular localization (Fig. 6E). Together, our data establish a strong
298 spatiotemporal and functional correlation between GLS expression in the nucleus and its role in
299 controlling delamination of NCCs.

300

301 **Glutaminase cooperates with Wnt signaling to control NCC delamination**

302 Delamination of NCCs in the trunk region is under the control of canonical Wnt-1 signaling [38]. The
303 most distinctive step of this pathway is the nuclear translocation of β -catenin, a modular protein either
304 associated with cadherins in intercellular contacts or capable of binding transcription factors in the
305 nucleus to regulate gene expression [39]. Previous investigations in delaminating and migratory NCCs
306 revealed a pattern of nuclear β -catenin localization similar to that observed for GLS in the present study
307 [40], prompting us to explore a possible link between Wnt signaling and a non-canonical function of GLS.
308 We therefore investigated whether β -catenin and GLS are co-distributed in NCCs in culture during
309 delamination and migration. We found that β -catenin was primarily accumulated in the nuclei with GLS
310 in delaminating NCCs (Fig. 7A,B). In contrast, β -catenin was mostly found in cell-cell contacts and rarely
311 in the nuclei of migratory NCCs, while GLS was essentially cytoplasmic (Fig. 7A,B). In embryos, we
312 confirmed GLS localization in the nuclei of NCCs at delamination, while β -catenin showed a diffuse
313 staining in both the cytoplasm and nucleus of cells and was faint in the areas of cell-cell contacts,
314 indicative of a nuclear shuttling activity (Fig. 7C). Importantly, depletion of nuclear GLS by CB-839 *in vitro*
315 or by siRNA *in vivo* caused β -catenin disappearance from the nucleus and cytoplasm of NCCs and its
316 redistribution into cell-cell contacts (Fig. 7B,C), raising the possibility that β -catenin and GLS may be
317 translocated to the nucleus in a coordinated manner. To address this question, we utilized the proximity
318 ligation assay (PLA), to investigate the interaction frequency between β -catenin and GLS. We found a
319 significantly greater number of puncta in the nuclei of delaminating NCCs than in migratory ones (Fig.
320 7D,E), and this number was markedly reduced in the presence of CB-839, strongly suggesting that
321 nuclear translocation of β -catenin in delaminating NCCs relies on GLS activity (Fig. 7E).

322 In addition to regulating expression of EMT-TFs, Wnt signaling in NCCs drives G1/S transition
323 during the cell cycle, at which step they segregate from the NT [34, 38]. We therefore investigated
324 expression of *cyclin-E*, a member of the cyclin family recruited at the G1/S transition [41, 42], in
325 delaminating and migrating NCCs. We found a higher expression of *cyclin-E* mRNAs in NCCs at
326 delamination than at migration (Fig. 7F). Interestingly, CB-839 negatively affected *cyclin-E* levels at both
327 stages while glutamate decreased *cyclin-E* expression only at delamination (Fig. 7G). Moreover,

328 glutamine deprivation also strongly decreased *cyclin-E* expression (Fig. 7G). In agreement with these
329 findings, EdU short-pulse experiments revealed that both CB-839 and glutamine starvation significantly
330 inhibited G1/S transition in NCCs, while glutamate had no effect (Fig. 7H). Altogether, our data indicate
331 that nuclear GLS associates with β -catenin, thus cooperating with Wnt signaling to regulate expression
332 of EMT-TFs and synchronize NCC delamination with the G1/S transition phase of the cell cycle.

333

334 DISCUSSION

335 Here, we report that NCCs engage different metabolic pathways during delamination and migration in
336 relation with specific gene networks, highlighting that glucose and glutamine are both required for these
337 events, each playing a specific role at each step (Fig. 8). In particular, we show *in vitro* and *in vivo* that
338 during delamination, NCCs exhibit a quiescent metabolic phenotype characterized by a limited energy
339 production due to combined low glycolytic and low mitochondrial respiration activities, yet they are
340 metabolically active. Indeed, delaminating NCCs show a preference for anabolic activity via the PP
341 pathway to support the many molecular changes occurring during EMT. During migration, in contrast,
342 NCCs exploit glucose and glutamine oxidation to fuel mitochondrial respiration for efficient energy
343 production. Thus, NCCs adapt their nutrient preference and use to their bioenergetics and biosynthetic
344 demands to their developmental program. Importantly, this metabolic switch is accompanied by
345 changes in the repertoire of the genes for metabolic enzymes deployed, which is characteristic of a
346 metabolic reprogramming. Moreover, we found that metabolic activity not only accommodates to NCC
347 development but also influences their developmental program, as revealed by functional experiments in
348 which blocking glutamine and glucose metabolism affected expression of EMT-TFs and of migration-
349 related genes, causing severe reduction in EMT and migration. Our data therefore uncover a poorly
350 investigated facet of EMT that acquisition of migratory abilities following EMT requires metabolic
351 rewiring in connection with profound cellular and molecular changes. How metabolic pathways are
352 regulated to enable transition from EMT to migration remains yet to be investigated.

353 An original aspect and great strength of our work is that we initially identified the metabolic
354 profile of NT cultures prior to performing any analysis of metabolite contribution and gene expression of
355 delamination and migration events. Thus, we could clearly assign a quiescent profile to delamination
356 and an OXPHOS-driven metabolism to migrating cells and confidently manipulate our experimental
357 conditions to investigate the metabolic and molecular mechanisms underlying these two main events in
358 NCC development. The reason for these two distinct metabolic phenotypes in primary cultures that

359 were carefully and identically prepared from embryos handled in the same way is unknown, although
360 we speculate that the *in ovo* environment somehow influences the behavior of cells after isolation.

361 A most important finding emerging from our study is the signaling role of glutamine during
362 delamination. This function is not mediated directly by glutamine itself but is executed by GLS, a key
363 enzyme of the glutamine pathway. There is increasing evidence that GLS is involved in EMT in cancers
364 [36]. For example, in colorectal cancers, GLS overexpression correlates with increased invasiveness and
365 patient mortality [43]. GLS also has critical role in development of prostate cancers and loss of GLS
366 results in cell cycle arrest and apoptosis [44]. However, the mechanism by which GLS contributes to cell
367 invasion remains elusive and has been mostly attributed to its bioenergetic role. Our data in NCCs
368 advance the understanding of this process, showing that GLS function in EMT is mainly dependent on its
369 nuclear localization and consequent modulation of EMT-TFs expression, while its enzymatic activity
370 leading to glutamate production is of minor importance during this event. This raises the intriguing
371 possibility that GLS exhibits a non-canonical gene regulatory function during NCC EMT. Several examples
372 of nuclear translocation of metabolic enzymes, such as pyruvate kinase M2, an enzyme of the glycolytic
373 pathway [17], have been reported in cancer cells in relation with EMT, but so far this has not been
374 reported for GLS.

375 A nuclear role for GLS is corroborated by our results demonstrating an interaction between GLS
376 and β -catenin and their concomitant nuclear accumulation in delaminating NCCs. Furthermore, we
377 found that blocking GLS with either an inhibitor (CB-839) or by siRNA abolished the nuclear shuttling of
378 both GLS and β -catenin. Our experiments do not allow us to determine whether GLS and β -catenin
379 associate before nuclear translocation or move to the nucleus separately and interact once there.
380 However, it is worth-mentioning that unlike GLS, β -catenin lacks a nuclear localization sequence in its
381 sequence [45, 46], raising the hypothesis that GLS might serve as a carrier for β -catenin. These findings
382 together with the observation that cyclin-E-dependent G1/S transition is dependent on GLS activity
383 emphasizes a novel critical role of GLS as a master gene regulator in NCC development where canonical
384 Wnt signaling controls multiple events, from induction, EMT, to lineage differentiation. Interestingly,
385 GLS inhibition in prostate cancer has been found to suppress Wnt/ β -catenin signaling and inhibit
386 proliferation via repression of cyclin-D1 [44].

387 The recent demonstration that avian cranial NCCs display a Warburg effect during delamination
388 and that this is coupled with genetic programs controlling cell identity and behavior highlighted the
389 parallel between NCCs and metastasis [3, 23]. However, this view was challenged by the fact that trunk
390 NCCs do not share this feature with cranial NCCs but instead elect a different metabolic process based

391 on glucose oxidation combined with mobilization of multiple metabolic pathways during migration [24].
392 Our present observation that trunk NCCs utilize nuclear shuttling of GLS as an important intermediate to
393 regulate the gene regulatory network involved in EMT is reminiscent once more of the situation
394 observed in cancer cells. This suggests that despite presenting distinct metabolic features, trunk NCCs
395 share with cancer cells similar processes to connect metabolic events with gene regulation during EMT,
396 establishing that the parallel made between cranial NCCs and cancer cells also applies to trunk NCCs.
397 Finally, these findings illustrates the great diversity of processes used by cells to accomplish their
398 developmental program and raise the possibility that metabolic activity might determine the scenario by
399 which cells undergo EMT.
400

401 MATERIALS AND METHODS

402 Reagents

403 Bovine plasma fibronectin, 1mg/ml stock, was from Sigma (cat. no. F1141). Dispase II at 5 U/ml stock
404 solution in Hanks' balanced saline was from Stemcell Technologies (cat. no. 07913). The following
405 chemical compounds were prepared and used according to the manufacturers' guidelines: 2-deoxy-D-
406 glucose (2-DG, Sigma, cat. no. D8375); oligomycin-A (Sigma, cat. no. 75351); rotenone (Sigma, cat. no.
407 R8875); antimycin-A (Sigma, cat. no. A8674); carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
408 (FCCP, Sigma, cat. no. C2920); 6-aminonicotinamide (6-AN, Cayman Chemicals, cat. no. 10009315); 6-
409 diazo-5-oxo-L-norleucine (DON, Sigma, cat no. D2141); and CB-839 (Sigma, cat. no. 5337170001). All
410 chemicals were used *in vivo* and *in vitro* at concentrations below those provoking long term-cellular
411 toxicity or overt morphological malformations. 2-DG was solubilized as a 1 M stock solution in DMEM
412 medium (without glucose, pyruvate and glutamine, Gibco, cat. no. A14430-01) and used at 10 mM;
413 oligomycin, rotenone, antimycin, and FCCP were prepared in DMSO as 10 mM stock solutions, diluted as
414 stock solution in culture medium at 100 μ M, and used at 1 μ M or 0.75 μ M (for FCCP); 6-AN was
415 prepared as a 100 mM solution in DMSO and used at 250-500 μ M; DON was prepared as a 30 mM stock
416 solution in H₂O and used at 30-60 μ M; and CB-839 was prepared as a 34 mM stock solution in DMSO and
417 used at 20-50 μ M. As 1/1000 dilution of DMSO had not effect on NCC behavior, in experiments using
418 this dilution, the corresponding controls were performed without addition of DMSO. When DMSO
419 dilution was below 1/1000, the same dilution of DMSO but without the drug was used for controls. Four
420 siRNAs corresponding to different regions of the Gallus gallus *GLS* mRNA were designed using the
421 sidirect2.rnai.jp website and purchased from Eurogentec: siRNA.1 GLS: 5'-
422 GAAAGGUUGCUGACUAUAUUC-3'; siRNA.2 GLS: 5'-CCAAAGUUCUUUUUGUCUUC-3'; siRNA.3 GLS: 5'-
423 GGAUUAAGAUUCAACAAAUUG-3'; siRNA.4 GLS: 5'-AUUUUUCUGCAUUAUUUGCUC-3'. The universal
424 siRNA negative control was purchased from Eurogentec.

425

426 Embryos

427 Quail embryos were used throughout the study. Fertilized eggs purchased from a local farm (La Caille de
428 Chanteloup, Corps Nuds, France) were incubated at 37-38°C until embryos reached the desired
429 developmental stages. Embryos were staged using the Hamburger and Hamilton (HH) chart [33] and
430 based on the number of somite pairs.

431

432 ***In ovo* injection of drugs and siRNAs**

433 *In vivo* loss-of-function experiments were performed on embryos at stage HH12 (15-16 somite pairs at
434 48 h of incubation), i.e. before onset of delamination. After removing 1 ml of albumin from the egg and
435 opening the shell with curved dissecting scissors to expose the embryo to the experimenter, a drop of
436 Fast Green solution was added on top of the vitelline membrane for easy visualization of the embryonic
437 tissues, and the drugs and siRNAs diluted at the desired concentration in PBS were injected using glass
438 pipets at the tail bud end of the embryo into the lumen of the NT and under the vitelline membrane in
439 the vicinity of the NT over the unsegmented region and the last 3-5 somites (10 μ l delivered per
440 injection). Controls embryos were injected with the vehicle only. The eggs were sealed with tape and
441 were further incubated at 37-38°C in a moist atmosphere for 5-24 h. Monitoring of NCC development
442 was performed by following expression of marker genes by qRT-PCR at 5 h and whole mount *in situ*
443 hybridization at 5 and 24 h followed by sectioning (see below).

444

445 **Cell culture**

446 **Generation of NCC primary cultures**

447 NCC cultures were produced from trunk NT obtained from quail embryos at different stages covering
448 the delamination process: stage HH12-13 (17-18 somite pairs), stage 13 (19-21 somite pairs) and HH14
449 (23-25-somite stage) as described [24, 35]. After opening the eggshell, the yolk was transferred into
450 phosphate-buffered saline (PBS). The embryo was cut off from the yolk and transferred into PBS in an
451 elastomer-containing dish. An embryo portion of about 750- μ m long was excised at the level of the last
452 5 somites with a scalpel under a stereomicroscope and subjected to mild enzymatic digestion by
453 treatment with dispase II at 2.5 U/ml for 5-10 minutes at room temperature. The NT was dissected out
454 manually using fine dissection pins under a stereomicroscope, freed from the surrounding tissues, and
455 transferred for 30-60 minutes in DMEM medium without glucose, pyruvate and glutamine (Gibco, cat.
456 no. A14430-01) supplemented with 0.5% fetal bovine serum, for recovery from enzyme treatment. NTs
457 were explanted onto a variety of substrates depending on the aim of the culture (plastic culture dishes,
458 Seahorse plates, chambered glass coverslips or glass coverslips), all coated with fibronectin at 10 μ g/ml
459 in PBS (i.e. about 5 μ g/cm²) for a minimum of 1 h at 37°C. To ensure rapid initiation of NCC migration,
460 NTs were positioned with their dorsal side oriented down toward the substratum. Explants were
461 cultured at 37°C under normoxic conditions in a 5%-CO₂ incubator in DMEM containing 1% serum, 100
462 U/ml penicillin, 100 μ g/ml streptomycin, and supplemented or not with 5 mM glucose, 2 mM glutamine
463 or both, depending on the aim of the experiment. In some experiments, glutamine was replaced by

464 glutamate (Sigma, cat. no. 49621) used at 10 μ M. The NT explants were followed and analyzed routinely
465 during the first 5 h of culture and up to 24 h in some experiments. Throughout each experiment, the
466 morphology of the NT explant, area and progression of the NCC outgrowth, as well as individual cell
467 shape were evaluated, imaged, and assessed regularly under an inverted phase contrast Nikon
468 microscope equipped with 6.3X, 10X, and 20X objectives.

469
470 **Quantifications of NCC numbers:** To quantify the number of NCCs in outgrowths, phase contrast images
471 of explants encompassing the whole NCC outgrowth were taken with the 10x objective at defined time
472 points of the culture. Cells were counted in a square of 100- μ m-side of the outgrowth using ImageJ and
473 data were reported to the entire outgrowth area measured using ImageJ. To analyze the delaminating
474 and migrating NCC populations in NT explants in culture at the end of the experiments, the NT was
475 removed manually from the dish by gentle flushing of culture medium with a pipet tip, thereby
476 uncovering delaminated cells situated underneath the NT [24]. Delaminating cells were discriminated
477 from migratory cells using several criteria: their strong Snail-2 content, their central position in the
478 outgrowth often separated from the migration zone by a cell-free gap, their reduced size, and their
479 compact shape. The numbers of delaminated and migrating cells were counted as above in a square of
480 100- μ m side covering the areas of delaminated cells or of migrating cells, in the mid-part of the explant
481 along its long axis and reported to the entire outgrowth area.

482
483 **Cellular bioenergetics analyses**

484 **Seahorse analyses:** Bioenergetics profiles of NCC primary cultures were determined using a Seahorse
485 Bioscience XF24 Analyzer as described [24]. A single NT explanted from embryos at HH13 was deposited
486 precisely at the center of each well of a 24-well Seahorse plate previously coated with fibronectin and
487 containing 100 μ l of culture medium, and NCCs were allowed to undergo migration for 2 h (Fig. S1B).
488 Before preparation of the plate for Seahorse analysis, phase contrast pictures of the NT explants were
489 taken and their areas were measured for normalization. Cultures were then rinsed in Seahorse XF
490 medium (Agilent, cat. no 103575-100) without serum and incubated for 30 minutes at 37°C in normal
491 atmosphere in 500 μ l assay medium supplemented with the same metabolites as prior to the rinsing
492 step, except serum. Then, the Seahorse assay was run according to the manufacturer's instructions.
493 After Seahorse metabolic profiling, NCC primary cultures were processed for cellular assays of
494 delamination and migration, immunolabeling, qPCR analyses, or intracellular ATP, glutamine or

495 glutamate measurements (Fig. S1B). All experiments were normalized with respect to both the NT
496 length and the stage of embryos at onset of experiments.

497 Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) values, as readouts of
498 basal mitochondrial respiration and lactate production, were assessed through 4 cycles of measurement
499 during 30 minutes, and in some experiments, this was followed by drug injections and 3 additional
500 cycles of measurement. All drugs solutions were prepared from stock solutions in assay medium
501 supplemented with glucose and glutamine. OCR and ECAR values were used to establish the energetic
502 maps of cells, comprising four quadrants (quiescent, aerobic (OXPHOS), glycolytic, and energetic) as
503 described previously [24]. The key parameters of mitochondrial respiration (ATP-linked respiration,
504 maximal respiratory capacity and proton leak) were measured by means of a MitoStress test after
505 sequential additions of oligomycin at 1 μ M, FCCP at 0.75 μ M, and rotenone + antimycin at 1 μ M through
506 3 cycles of measurements in 30 minutes. Coupling efficiency, which represents the proportion of
507 respiratory activity that is used to make ATP, was calculated as the difference between the basal OCR
508 and the minimal, ATP-linked OCR. Spare respiratory capacity, which corresponds to the extra
509 mitochondrial capacity available in a cell to produce energy under conditions of increased demand, was
510 calculated as the difference between the maximal OCR and the basal OCR [47-49].

511 Temporal metabolic changes of NTs were investigated using two rounds of Seahorse assays on
512 the same explants. After identifying the initial metabolic profile of NT explants at the first 3 h of culture,
513 the plate was removed from the analyzer, the assay medium was changed for 100 μ l of fresh culture
514 medium and the plate was further incubated for overnight at 37°C in a 5%-CO₂ incubator and then
515 proceeded for the second run of Seahorse assay under the same conditions as for the first one.

516
517 **ATP and metabolite measurements:** Intracellular ATP and glutamine/glutamate levels were measured
518 for each NCC primary cultures after Seahorse analysis using the ATPlite Bioluminescence assay kit from
519 PerkinElmer (cat. no. 6016943), and the Glutamine/Glutamate-Go assay (J8021) assay kit from Promega
520 (cat. no. J8021), respectively, following the manufacturers' instructions. Measures were normalized to
521 NCC numbers.

522 523 **Cryosectioning**

524 To obtain embryo sections for immunolabeling or following in situ hybridization, embryos were washed
525 in PBS for 1 h at room temperature and in 15% sucrose solution overnight at 4°C. Next, they were
526 incubated in 7.5% porcine gelatin (dissolved in 15% sucrose solution) for 2-3 h at 40°C, embedded in

527 gelatin-sucrose in cup, snap-frozen in chilled isopentane at -70°C and stored at -80°C . 20- μm sections
528 were obtained using the Leica cryostat and collected on Superfrost/Plus slides (Thermo Fisher Scientific).
529 For imaging, the slides were immersed in PBS at 40°C for 2 h for gelatin removal, washed in PBS and
530 mounted in Aquatex mounting medium (Merck). Sections of embryos with in situ hybridization were
531 observed and imaged with a Hamamatsu NanoZoomer Digital Slide Scanner and treated with NDP.View2
532 software. Immunolabeled sections were observed with confocal microscope 20X fluorescence
533 objectives.

534

535 **Immunofluorescence labeling of NCC cultures and embryo sections**

536 For immunolabeling, the following primary antibodies were used: Rabbit monoclonal antibody (mAb) to
537 Snail-2 (clone C19G7, Cell Signaling, 1/300), mouse mAb to Sox-10 (Clone A2, Santa Cruz, 1/200), mouse
538 mAb to β -catenin (clone 14, BD-Transduction Laboratories, 1/200), and rabbit polyclonal antibodies to
539 GLS (PA535365, Life Technologies, 1/50). NCC primary cultures were performed on glass coverslips
540 deposited in 4-well plates (Nunc, cat. no. 144444) or in 8-well Lab-Tek Chambered Coverglass (Nunc, cat.
541 no. 154511) coated with fibronectin. After removing the NT to uncover delaminating NCC, the cultures
542 were fixed in 4% paraformaldehyde (PFA) in PBS for 15 minutes at room temperature for detection of all
543 antigens, except β -catenin (45 minutes in 1.5% PFA). After permeabilization with 0.5% Triton X-100 in
544 PBS for 5 minutes and washes in PBS, cultures were blocked in PBS-3% BSA and subjected to
545 immunofluorescence labeling using primary antibodies followed by incubation with appropriate
546 secondary antibodies conjugated to Alexa-fluor 488 or Cy-3 (Jackson ImmunoResearch Laboratories), and
547 processed for DAPI or Hoechst staining to visualize cells' nuclei before mounting in ImmuMount medium
548 (Shandon). For immunostaining of embryo sections, essentially the same procedure was used.
549 Preparations were observed with a Zeiss AxioImager M2 epifluorescence microscope equipped with
550 20X-63X fluorescence objectives (Acroplan 10X/0.25, 20X/0.45, Plan-Neofluar 40X/0.75 and 63X/1.25
551 oil) or using z-stack acquisitions with a Zeiss LSM 900 confocal microscope equipped with 10X-40X
552 fluorescence objectives (Plan-Apochrome 40X/1.30 oil). Data were collected using the Zen or Airyscan2
553 software and processed using ImageJ software.

554

555 **Whole mount immunolabeling**

556 Trunk regions of embryos were fixed with 4% PFA for 2 hours at 4°C , washed 2 times with PBS + 0.1%
557 Triton X100 for 5 minutes, and incubated with blocking solution (PBS + 0.1% Triton X100 + 1% BSA and
558 0.15 % (w/v) glycine) for 2 days at 4°C under stirring. They were then incubated for one night at 4°C

559 with gentle shaking with primary antibodies to GLS (1:50) and Sox-10 (1:200) in blocking solution. In the
560 following day, the embryos were washed 3 times for 20 minutes with blocking solution at room
561 temperature and then incubated for another night with secondary antibodies conjugated to Cy3 and
562 Alexa-fluor 488 (1:300) in blocking solution as for the primary antibodies. Lastly, embryos were washed
563 3 times for 20 minutes with blocking solution and transferred into a Coverwell imaging chamber (Grace
564 Bio Lab, cat. no. 635041) with their dorsal side oriented toward the bottom. After removing the bulk of
565 liquid to keep them flat, a few droplets of mounting medium were added before mounting with a
566 coverslip, and the preparations were kept for 24 hours at room temperature before imaging with
567 confocal microscope 20X fluorescence objectives.

568

569 **Proximity ligation assay (PLA)**

570 After 5 hours in culture and removing the NT to uncover delaminating NCC, explants were fixed with 4%
571 PFA for 15 minutes, followed by permeabilization with 0.5% Triton X-100 in PBS for 5 minutes, rinsing in
572 PBS and blocking in PBS-3% BSA. Cultures were then subjected to immunofluorescence labeling using
573 pairs of primary mouse and rabbit antibodies to β -catenin and GLS diluted in blocking solution as
574 described above. Non-immune mouse antibodies (Jackson ImmunoResearch, cat. no 015-000-002) were
575 used instead of mouse mAb to β -catenin for controls. Following primary antibodies incubation, the
576 cultures were washed 3 times in PBS for 5 minutes and incubated with Duolink Plus and Minus PLA
577 probes (diluted 1:5) followed by Duolink In Situ Orange Starter Kit Mouse/Rabbit (Sigma, cat. no.
578 DUO92102), according to the manufacturer's guidelines. Confocal microscopy image acquisition was
579 performed as above and quantitative analysis of PLA-positive dots was done on Z-projection images
580 through the entire cell using ImageJ.

581

582 **In situ hybridizations for mRNA detection on whole mount embryos**

583 In situ hybridization mRNA probes were generated either by PCR (for *GLS* and *GDH*) or from plasmid
584 vectors (for *Sox-10* and *Foxd-3*). For PCR probes, primers were designed to generate a 400-500 bp
585 fragment of the mRNA coding sequence based on information available from NCBI databases. The
586 following forward and reverse sequences were selected for *GLS*, *fwd* 5'-
587 GAAGGACAAGAGAAAATACCAAGTG-3', *rev* 5'-TGCTCCAGCATTCACCATAGG-3'; *GDH*, *fwd* 5'-
588 TGGGACAATCATGGGCTTCC-3', *rev* 5'-CAGTACGCATGATTTGTCGAGC-3'; and *SNAT-2*, *fwd* 5'-
589 TACGCTGTCCCAATCCTGAC-3', *rev* 5'-TGCTGCAGATGCACCAATGAAT-3' and the PCR primers were
590 designed as follows. The linker, 5'-GAG-3', and the sequence of the RNA polymerase T7 binding site, 5'-

591 TAATACGACTCACTATAGGG-3', were added to the reverse sequences. The synthesized PCR primers
592 (Eurogentec) were used to generate SNAT-2, GLS, and GDH probes by PCR reaction performed with chick
593 embryo cDNA template using Platinum Taq DNA polymerase (Invitrogen, cat. no. 10966018). PCR
594 products were assessed on a gel and purified using the Qiaquick PCR Cleanup kit (Qiagen, cat. no.
595 28104). Plasmids for *Foxd-3* and *Sox10* mRNA probe synthesis were from C. Erickson and P. Scotting,
596 respectively [50, 51]. Linearized plasmid DNA and PCR products were used to synthesize digoxigenin-
597 UTP (Roche) labeled antisense probes with RNA polymerases from Promega and RNA probes were
598 purified with Illustra ProbeQuant G-50 microcolumns (GE Healthcare, cat. no. 28903408).

599 In situ hybridizations were performed on whole mount embryos collected at the appropriate
600 developmental stages, and fixed in 4% PFA in PBS for 2 h at room temperature or overnight at 4°C.
601 Embryos were hybridized overnight at 65°C with the digoxigenin-UTP-labeled RNA probes in 50%
602 formamide, 10% dextran sulfate and Denhart's buffer (0.5 µg probe/ml hybridization buffer) and
603 washed twice in 50% formamide, 1x SSC and 0.1% Tween-20 at 65°C, then 4 times at room temperature
604 in 100 mM maleic acid, 150 mM NaCl pH 7.5 and 0.1% Tween-20 (MABT buffer). After a 1-h pre-
605 incubation in MABT buffer containing 10% blocking reagent (Roche) and 10% heat-inactivated lamb
606 serum, embryos were incubated overnight at room temperature with the anti-digoxigenin antibody
607 (Roche). After extensive rinsing with MABT buffer, they were preincubated in 100 mM NaCl, 50 mM
608 MgCl₂, 1% Tween-20, and 25 mM Tris-HCl, pH 9.5, and stained with NBT-BCIP (Roche) following
609 manufacturer's guidelines. Preparations were observed and imaged with a Nikon stereomicroscope.

610

611 **mRNA quantification by quantitative RT-PCR analyses**

612 For NT explants cultured in vitro, after characterizing the metabolic profiles of individual explants by
613 Seahorse analysis, total RNA of explants sharing the same metabolic profile were isolated using Trizol
614 (Invitrogen), following the manufacturer's instructions. For normal, untreated embryos and for embryos
615 injected with drugs or siRNAs, the NT situated in the caudal part encompassing the last 5 somites up to
616 the tail bud was dissected manually with fine dissection pins, and the total RNA was extracted using
617 Trizol (Fig. S1C, D). 500 ng RNA were used for cDNA synthesis using SuperScript IV reverse transcriptase
618 (Invitrogen, cat. no. 18090050). Quantitative real-time PCR were performed using the Power Syber
619 Green Master Mix (Applied Biosystems, cat. no. 4368708) in a StepOne Plus RT-PCR apparatus (Applied
620 Biosystems). Gene expression was assessed by the comparative CT ($\Delta\Delta_{Ct}$) method with β -actin as the
621 reference gene.

622 The following primers were used:

<i>Snail2fwd</i>	GATGCGCTCGCAGTGATAGT
<i>Snail2rev</i>	AGCTTTCATACAGGTATGGGGATA
<i>Cad6Bfwd</i>	ACCGTGAAAACAGGGAGCAA
<i>Cad6Brev</i>	TGAATTGGTAGGTGCTCTGGG
<i>cMycfwd</i>	GCAGCGACTCGGAAGAAGAACAAGAA;
<i>cMycrev</i>	GGTGGGGCTTACAGTGCTCC
<i>Sox10fwd</i>	CGGAGCACTCTTCAGGTCAG
<i>Sox10rev</i>	CCCTTCTCGCTTGGAGTCAG
<i>Foxd3fwd</i>	TCTGCGAGTTCATCAGCAAC
<i>Foxd3rev</i>	TTCACGAAGCAGTCGTTGAG
<i>Glut1fwd</i>	AAGATGACAGCTCGCCTGATG
<i>Glut1rev</i>	AGTCTTCAATCACCTTCTGCGG
<i>PFKfwd</i>	TTGGAATTGTCAGTGCCCC
<i>PFKrev</i>	TGCAGACAACCTTTCATAGGCATCAG
<i>LDHfwd</i>	GAGCGGAGTGAATGTTGCTG
<i>LDHrev</i>	ACCTCATAGGCACTGTCCAC
<i>PDHXfwd</i>	CTGCTGCTGACTGTGACATTG
<i>PDHXrev</i>	TCACATCTGGCATTGCTTCA
<i>PRPSfwd</i>	GCATCTCAGATTCAGGGCTTT
<i>PRPSrev</i>	GTCACTCTCTTGGCTCCACC
<i>GLSfwd</i>	GTCGCCCTCTTGGACAAGA
<i>GLSrev</i>	GCACAGAGAAACCAGATCATGACA
<i>GDHfwd</i>	GGAGATGTCCTGGATCGCTG
<i>GDHrev</i>	CCCACGTTACCAAATCCCTGA
<i>GLULfwd</i>	TGGAGGTCTCAAGCACATCG
<i>GLULrev</i>	AGCCTTTCTTCTCATGGCCC
<i>SNAT2fwd</i>	AGCAACGACTTCAGCTACCC
<i>SNAT2rev</i>	GGAAGTGGTACCCGGATGATAC
<i>CyclinEfwd</i>	GCTCCTGAAGACTTGACAAT
<i>CyclinErev</i>	TTTGCTTGAGCTTTGTCCAGC
<i>βActinfwd</i>	CTGTGCCCATCTATGAAGGCTA
<i>βActinrev</i>	ATTTCTCTCTCGGCTGTGGTG

623

624 **Cell Cycle Assay**

625 Cell cycling in culture was monitored using the Plus EdU Cell Proliferation Kit for Imaging from Life
626 Technologies (cat. no. C10638). Briefly, NCC primary cultures were incubated with EdU at 20 μM in
627 culture medium for 1 h. Immediately after EdU incorporation, cultures were fixed in 4% PFA in PBS for
628 15 minutes at room temperature, permeabilized in 0.5 Triton-X100 for 15 minutes and treated for EdU

629 detection using Alexa-555 Fluor azide in accordance with the manufacturer's guidelines. After DNA
630 staining with Hoechst, cultures were examined as described for immunolabelings.

631

632 **Cell locomotion assay**

633 NCC primary cultures were performed in 4-well Chambered Coverglass (Nunc, cat. no. 155383) coated
634 with fibronectin. Up to 5 NT were distributed separately into each well, and were maintained at 37°C in
635 a humidified 5%-CO₂ incubator for about 2 h until the NT adhered firmly to the dish and NCC initiated
636 migration on the substratum; then the cultures were transferred into a heated chamber (Ibidi) with a
637 humid atmosphere containing 5% CO₂/95% air placed on the motorized stage of a Leica DMIRE2
638 microscope equipped with a CoolSNAP HQ camera (Roper Scientific). Time-lapse video microscopy was
639 performed with a 10X objective and phase contrast images were captured every 5 minutes during 16-24
640 h using the Micromanager software. Trajectories and positions of individual NCC in several NT explants
641 recorded in parallel were tracked using Metamorph 7 software. The progression of the migration front
642 of the NCC population every hour was measured using a custom GUI (available upon request) written in
643 MATLAB (MathWorks., Natick, MA, USA). Trajectories and positions of individual NCCs in several
644 explants recorded in parallel were tracked using Metamorph 7 software. The velocity of each NCC was
645 calculated as the ratio between the total length of its trajectory and the duration of the acquisition time.

646

647 **Statistical methods**

648 Statistical analyses were performed using Prism 7 (GraphPad). For statistical analysis of data, we used
649 One-way ANOVA parametric test after the validation of normality and equality of variances using
650 Shapiro-Wilk and Brown-Forsythe methods, respectively. For comparison between two conditions we
651 used unpaired t-test two-tailed test after the validation of normality and equality of using Shapiro-Wilk
652 and equality of variances. Otherwise, non-parametric Mann-Whitney test was used. Unless specified, at
653 least three independent experiments were carried out for each procedure. Each NT explant was
654 considered as an individual sample. The data obtained for each drug or nutrient condition were
655 compared to that of the medium without drug or with both nutrients, respectively. The number of
656 samples n (explants or embryos) analyzed is indicated in each graph in brackets. For statistical analysis
657 of qRT-PCR results of in-vitro experiments, mRNA expression from a pool of 1-8 NT explants are
658 presented as mean ± s.e.m of triplicates per experiment and gene. In *in-vivo* experiments, mRNA
659 expression was measured per embryo after analyzing of three replicates measurements acquired per
660 embryo and genes. The data obtained from embryos injected with drugs were analyzed using Two-way

661 ANOVA relative to the data of embryos injected with vehicle. Data are expressed as mean values \pm
662 s.e.m. Results are considered statistically significantly different when $p < 0.05$.

663

664 **ACKNOWLEDGMENTS**

665 We deeply thank Chantal Thibert and Sakina Torch for providing advice in cellular metabolism. Special
666 thanks to Redouane Fodil for designing the software to track the progression of the migratory front of
667 NCC populations. Many thanks to Xavier Decrouy from the IMRB imaging platform and Xavier Laffray
668 from the histology and imaging platform of the Laboratoire Gly-CRRET for advice.

669

670 **COMPETING INTERESTS**

671 The authors declare no competing financial interests.

672

673 **AUTHOR CONTRIBUTIONS**

674 N.N.-M. conceived the project and designed the experimental approach, performed experiments,
675 analyzed data, and contributed to the manuscript. A.D. provided expertise for *in ovo* studies and
676 facilities for cryo-sectioning methods and analyses. F.R. provided financial and logistics support. R.F. and
677 R.M. provided expertise in cellular metabolism and Seahorse technology and revised the manuscript.
678 S.D. designed the experimental approach, performed experiments, analyzed the data, and contributed
679 to the manuscript. J.-L.D. designed the experimental approach, performed experiments, analyzed the
680 data, and wrote the manuscript.

681

682 **FUNDING**

683 This work was supported by funding from Institut National de la Santé et de la Recherche Médicale,
684 Université Paris-Est Créteil, AAP IMRB cross-teams project, and Fondation ARC pour la Recherche sur le
685 Cancer (No. PJA 20181207844). N.N.-M. was funded by doctoral fellowship of Université Paris-Est Créteil
686 and by the Labex REVIVE.

687

688 **REFERENCES**

- 689 1. Thiery, J.P., et al., *Epithelial-mesenchymal transitions in development and disease*. Cell, 2009. **139**(5): p.
690 871-90.
- 691 2. Lamouille, S., J. Xu, and R. Derynck, *Molecular mechanisms of epithelial-mesenchymal transition*. Nat Rev
692 Mol Cell Biol, 2014. **15**(3): p. 178-96.

- 693 3. Bhattacharya, D., B. Khan, and M. Simoes-Costa, *Neural crest metabolism: At the crossroads of*
694 *development and disease*. *Dev Biol*, 2021. **475**: p. 245-255.
- 695 4. Fedele, M., et al., *The Epithelial-Mesenchymal Transition at the Crossroads between Metabolism and*
696 *Tumor Progression*. *Int J Mol Sci*, 2022. **23**(2).
- 697 5. Georgakopoulos-Soares, I., et al., *EMT Factors and Metabolic Pathways in Cancer*. *Front Oncol*, 2020. **10**:
698 p. 499.
- 699 6. Jia, D., et al., *Towards decoding the coupled decision-making of metabolism and epithelial-to-*
700 *mesenchymal transition in cancer*. *Br J Cancer*, 2021. **124**(12): p. 1902-1911.
- 701 7. Jiang, L., et al., *Metabolic reprogramming during TGF β 1-induced epithelial-to-mesenchymal transition*.
702 *Oncogene*, 2015. **34**(30): p. 3908-16.
- 703 8. Dong, C., et al., *Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like*
704 *breast cancer*. *Cancer Cell*, 2013. **23**(3): p. 316-31.
- 705 9. Kim, N.H., et al., *Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing*
706 *cancer cell survival under metabolic stress*. *Nat Commun*, 2017. **8**: p. 14374.
- 707 10. Schito, L. and G.L. Semenza, *Hypoxia-Inducible Factors: Master Regulators of Cancer Progression*. *Trends*
708 *Cancer*, 2016. **2**(12): p. 758-770.
- 709 11. Yang, M.H., et al., *Direct regulation of TWIST by HIF-1 α promotes metastasis*. *Nat Cell Biol*, 2008.
710 **10**(3): p. 295-305.
- 711 12. Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson, *Understanding the Warburg effect: the metabolic*
712 *requirements of cell proliferation*. *Science*, 2009. **324**(5930): p. 1029-33.
- 713 13. Liberti, M.V. and J.W. Locasale, *The Warburg Effect: How Does it Benefit Cancer Cells?* *Trends Biochem Sci*,
714 2016. **41**(3): p. 211-218.
- 715 14. Kaelin, W.G., Jr. and S.L. McKnight, *Influence of metabolism on epigenetics and disease*. *Cell*, 2013. **153**(1):
716 p. 56-69.
- 717 15. Ahmad, A., et al., *Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal*
718 *transition regulated by miR-200 in breast cancer cells*. *Cancer Res*, 2011. **71**(9): p. 3400-9.
- 719 16. Liu, K., et al., *Glyceraldehyde-3-phosphate dehydrogenase promotes cancer growth and metastasis*
720 *through upregulation of SNAIL expression*. *Int J Oncol*, 2017. **50**(1): p. 252-262.
- 721 17. Hamabe, A., et al., *Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-*
722 *mesenchymal transition*. *Proc Natl Acad Sci U S A*, 2014. **111**(43): p. 15526-31.
- 723 18. Bronner, M., *Riding the crest for 150 years!* *Dev Biol*, 2018. **444 Suppl 1**: p. S1-s2.
- 724 19. Trainor, P., *Neural Crest Cells: Evolution, Development and Disease*. 2013: Elsevier. 488.
- 725 20. Duband, J.L., *Diversity in the molecular and cellular strategies of epithelium-to-mesenchyme transitions:*
726 *Insights from the neural crest*. *Cell Adh Migr*, 2010. **4**(3): p. 458-82.
- 727 21. Duband, J.L., A. Dady, and V. Fleury, *Resolving time and space constraints during neural crest formation*
728 *and delamination*. *Curr Top Dev Biol*, 2015. **111**: p. 27-67.
- 729 22. Kalcheim, C., *Neural crest emigration: From start to stop*. *Genesis*, 2018. **56**(6-7): p. e23090.
- 730 23. Bhattacharya, D., A.P. Azambuja, and M. Simoes-Costa, *Metabolic reprogramming promotes neural crest*
731 *migration via Yap/Tead signaling*. *Dev Cell*, 2020. **53**(2): p. 199-211.e6.
- 732 24. Nekooie Marnany, N., et al., *Glucose oxidation drives trunk neural crest cell development and fate*. *J Cell*
733 *Sci*, 2023. **136**(16).
- 734 25. Rothstein, M. and M. Simoes-Costa, *On the evolutionary origins and regionalization of the neural crest*.
735 *Semin Cell Dev Biol*, 2023. **138**: p. 28-35.
- 736 26. Théveneau, E., J.-L. Duband, and M. Altabef, *Ets-1 confers cranial features on neural crest delamination*.
737 *PLoS ONE*, 2007. **2**(11): p. e1142.
- 738 27. Duband, J.-L., *Neural crest delamination and migration*. *Neural Crest Induction and Differentiation*, 2006:
739 p. 45-77.
- 740 28. Rekler, D. and C. Kalcheim, *From Neural Crest to Definitive Roof Plate: The Dynamic Behavior of the Dorsal*
741 *Neural Tube*. *International Journal of Molecular Sciences*, 2021. **22**(8): p. 3911.
- 742 29. Dady, A. and J.L. Duband, *Cadherin interplay during neural crest segregation from the non-neural*
743 *ectoderm and neural tube in the early chick embryo*. *Developmental Dynamics*, 2017. **246**(7): p. 550-565.
- 744 30. Duband, J.-L., A. Dady, and V. Fleury, *Resolving time and space constraints during neural crest formation*
745 *and delamination*. *Current topics in developmental biology*, 2015. **111**: p. 27-67.

- 746 31. Simoes-Costa, M. and M.E. Bronner, *Reprogramming of avian neural crest axial identity and cell fate*.
747 Science, 2016. **352**(6293): p. 1570-1573.
- 748 32. Schock, E.N. and C. LaBonne, *Sorting Sox: Diverse roles for Sox transcription factors during neural crest and*
749 *craniofacial development*. Front Physiol, 2020. **11**: p. 606889.
- 750 33. Hamburger, V. and H.L. Hamilton, *A series of normal stages in the development of the chick embryo*. J
751 Morphol, 1951. **88**(1): p. 49-92.
- 752 34. Burstyn-Cohen, T. and C. Kalcheim, *Association between the cell cycle and neural crest delamination*
753 *through specific regulation of G1/S transition*. Develop. Cell, 2002. **3**: p. 383-395.
- 754 35. Duband, J.L., N. Nekooie-Marnany, and S. Dufour, *Establishing primary cultures of trunk neural crest cells*.
755 Curr Protoc Cell Biol, 2020. **88**(1): p. e109.
- 756 36. Altman, B.J., Z.E. Stine, and C.V. Dang, *From Krebs to clinic: glutamine metabolism to cancer therapy*. Nat
757 Rev Cancer, 2016. **16**(10): p. 619-34.
- 758 37. Gross, M.I., et al., *Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer*.
759 Mol Cancer Ther, 2014. **13**(4): p. 890-901.
- 760 38. Burstyn-Cohen, T., et al., *Canonical Wnt activity regulates trunk neural crest delamination linking*
761 *BMP/noggin signaling with G1/S transition*. Development, 2004. **131**(21): p. 5327-39.
- 762 39. Wodarz, A. and R. Nusse, *Mechanisms of Wnt signaling in development*. Annu Rev Cell Dev Biol, 1998. **14**:
763 p. 59-88.
- 764 40. de Melker, A.A., N. Desban, and J.L. Duband, *Cellular localization and signaling activity of b-catenin in*
765 *migrating neural crest cells*. Develop. Dyn., 2004. **230**(4): p. 708-26.
- 766 41. Caldon, C.E. and E.A. Musgrove, *Distinct and redundant functions of cyclin E1 and cyclin E2 in development*
767 *and cancer*. Cell division, 2010. **5**(1): p. 1-13.
- 768 42. Yang, K., M. Hitomi, and D.W. Stacey, *Variations in cyclin D1 levels through the cell cycle determine the*
769 *proliferative fate of a cell*. Cell division, 2006. **1**(1): p. 1-8.
- 770 43. Xiang, L., et al., *Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for*
771 *tumor growth, invasion, and metastatic colonization*. Cell death & disease, 2019. **10**(2): p. 1-15.
- 772 44. Zhang, J., et al., *Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer*.
773 Bioscience reports, 2019. **39**(6).
- 774 45. Anthony, C.C., et al., *Nuclear regulation of Wnt/ β -catenin signaling: it's a complex situation*. Genes, 2020.
775 **11**(8): p. 886.
- 776 46. Fagotto, F., U. Glück, and B.M. Gumbiner, *Nuclear localization signal-independent and*
777 *importin/karyopherin-independent nuclear import of β -catenin*. Current Biology, 1998. **8**(4): p. 181-190.
- 778 47. Ferrick, D.A., A. Neilson, and C. Beeson, *Advances in measuring cellular bioenergetics using extracellular*
779 *flux*. Drug discovery today, 2008. **13**(5-6): p. 268-274.
- 780 48. Oburoglu, L., et al., *Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage*
781 *specification*. Cell stem cell, 2014. **15**(2): p. 169-184.
- 782 49. Winer, L.S.P. and M.J.P.o. Wu, *Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a*
783 *microplate*. 2014. **9**(10): p. e109916.
- 784 50. Kos, R., et al., *The winged-helix transcription factor FoxD3 is important for establishing the neural crest*
785 *lineage and repressing melanogenesis in avian embryos*. Development, 2001. **128**: p. 1467-1479.
- 786 51. Cheng, Y., et al., *Chick sox10, a transcription factor expressed in both early neural crest cells and central*
787 *nervous system*. Brain Res Dev Brain Res, 2000. **121**(2): p. 233-41.
- 788 52. Kerosuo, L. and M.E. Bronner, *cMyc regulates the size of the premigratory neural crest stem cell pool*. Cell
789 Rep, 2016. **17**(10): p. 2648-2659.

790

791

792 **FIGURES**

793 **Figure 1: NCC transition from delamination to migration is coupled to metabolic switch**

794 **Figure 2: A change in glucose utilization accompanies NCC transition from delamination to**
795 **migration**

796 **Figure 3: Glutamine metabolism is required for NCC delamination and migration**

797 **Figure 4: Glutaminase is required for NCC delamination and migration**

798 **Figure 5: Glutaminase exhibits a non-canonical function during NCC delamination**

799 **Figure 6: Glutaminase translocates to the nucleus in delaminating NCCs**

800 **Figure 7: Glutaminase cooperates with Wnt signaling to control NCC delamination**

801 **Figure 8: NCC cellular metabolism is coupled to developmental program**

802

803




Figure 1: Nekoie Marnany et al.

804

805

806 **Figure 1: NCC transition from delamination to migration is coupled to metabolic switch**

807 (A) Schematic representation of the gene regulatory network controlling NCC delamination and
808 migration in the trunk region of the avian embryo. The top diagram depicts transverse views through the
809 NT at the thoracic level at stages HH12, HH13 and HH14, showing the pre-migratory (grey), delaminating
810 (red), and migrating (green) NCC populations. ec, ectoderm; no, notochord; nt, neural tube. The bottom
811 diagram depicts the expression profiles of markers of NCC delamination and migration over time. (B)
812 Energetic maps of the two metabolic profiles, quiescent (yellow) and OXPHOS (blue), obtained from the
813 analysis of a large panel of explants at HH12-13 to HH14-15 cultured for 3 h in medium with glucose and
814 glutamine. Data represent the mean values \pm s.e.m. of OCR and ECAR. (C) Scatter dot plot of the
815 OCR/ECAR ratio (mean \pm s.e.m.) in NT explants with quiescent and OXPHOS profiles. (D) Mitochondrial
816 stress assays of individual trunk NT explants with quiescent (top) and OXPHOS (bottom) profiles showing
817 OCR and ECAR changes over time. Data were collected from at least three independent experiments. (E-
818 G) Metabolic parameters (mean values \pm s.e.m.) of NT explants with quiescent and OXPHOS profiles of:
819 basal, minimal, and maximal OCR (E); coupling efficiency and spare respiratory capacity (F); and ATP
820 levels (G). (H) Phase contrast images of NT explants with quiescent and OXPHOS profiles after 3 h in
821 culture. The outermost boundary of the NCC outgrowth on either side of the NT is delineated in red. ncc,
822 neural crest cells; nt, neural tube. Bar = 100 μ m. (I) Scatter dot plots of the number of migrating NCCs
823 per explants (mean \pm s.e.m.) with quiescent and OXPHOS profiles after 3 h of culture. (J) Scatter dot plot
824 of normalized mRNAs levels (mean \pm s.e.m.) measured by qRT-PCR of delamination and migration
825 markers in NT explants with quiescent and OXPHOS profiles. *c-Myc*, a gene expressed by delaminating
826 and migrating NCCs but not implicated in EMT [52], was used as an internal control. (K) Energetic maps
827 of 9 individual explants with an initial quiescent metabolic profile at 3 h of culture showing a switch to
828 an OXPHOS profile after 20 h. (L) Proportions of quiescent and OXPHOS profiles in trunk NT explants at
829 the thoracic level from HH12-13 and HH14-15 embryos, respectively. (M) Scatter dot plot of the number
830 of migrating NCCs per explant (mean \pm s.e.m.) at stages HH12-13 and HH14-15 after 3 h in culture. (N)
831 Diagram depicting the coupling between the transition from delamination to migration and the
832 metabolic shift from quiescence to OXPHOS in trunk NCCs. Images in H are from representative
833 experiments. In panels B-I and K-M, (n) indicate the number of explants analyzed, and in J, (n) indicate
834 the number of experiments with the measurements done in triplicates for each gene. In panels C, F, G, I
835 and M, data were analyzed using unpaired two-tailed *t*-test. ns, not significantly different, $P > 0.05$.

836




Figure 2: Nekooie Marnany et al.

838 **Figure 2: A change in glucose utilization accompanies NCC transition from delamination to**
839 **migration**

840 (A) Schematic representation of the most relevant metabolic pathways downstream of glucose and
841 glutamine uptakes and their interconnections with the PP and OXPHOS pathways. The main enzymes
842 within each pathway analyzed in this study as well as the specific metabolic inhibitors used are
843 indicated. (B). Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m.) measured by qRT-PCR of
844 genes encoding glycolytic enzymes in cultured NT explants with quiescent (yellow) and OXPHOS (blue)
845 profiles (left) and in NTs collected from the trunk region of HH12-13 (red) and HH14 (green) embryos
846 (right). (C, D) Effect of inhibitors of glycolysis (2-DG, triangles), OXPHOS (Oligomycin, squares), and PP
847 pathways (6-AN, diamonds) compared with medium without drug (circles) on metabolic parameters (C)
848 and ATP levels (D) of NT explants at the delamination (quiescent, top panels) and migration (OXPHOS,
849 bottom panels) stages: energetic maps defined by OCR and ECAR as mean values \pm s.e.m. (C, left panels);
850 scatter dot plots of the OCR/ECAR ratio as mean \pm s.e.m. (C, right panels). OCR and ECAR were recorded
851 in individual explants before and after inhibitor treatment and ATP levels were measured after two
852 additional hours in the presence of the inhibitor. (E) Changes in OCR and ECAR over time of individual
853 trunk NT explants with quiescent (left) and OXPHOS (right) profiles before and after addition of 6-AN.
854 Data were collected from at least three independent experiments. (F) Scatter dot plot of normalized
855 mRNAs levels (mean \pm s.e.m.) measured by qRT-PCR of *LDH*, *PFK* and *PRPS* in the trunk of embryos 5 h
856 after 6-AN or vehicle (no-drug) injection. Embryos were injected either at HH12-13 (red) or at HH14
857 (green). In panel B left, (n) indicates the number of experiments with the measurements done in
858 triplicates for each gene; in panels B right and F, (n) indicate the number of embryos, with the
859 measurements done in triplicates for each gene. In C-E, (n) indicate the number of explants analyzed.
860 Data in B and F were analyzed using unpaired two-tailed *t*-test. Data in C and D were analyzed using one-
861 way ANOVA followed by Dunnett's multiple comparison tests relative to the condition with quiescent
862 profile. ns, not significantly different, $P > 0.05$.

863




Figure 3: Nekoie Marnany et al.

865 **Figure 3: Glutamine metabolism is required for NCC delamination and migration**

866 (A) Whole mount views of the trunk of HH13 quail embryos hybridized with probes for the players in
867 glutamine metabolism *SNAT-2*, *GLS*, and *GDH*, and for *Foxd-3* used as a reference marker for the axial
868 levels of NCC delamination and migration; anterior to the top. In situ hybridizations for each probe were
869 done in triplicate. nt, neural tube; pm; unsegmented paraxial mesoderm; so, somite. Bar = 500 μ m. (B)
870 Cross-sections through the caudal half of whole-mount embryos hybridized with probes for *SNAT-2*, *GLS*,
871 *GDH* and *Foxd-3* showing the dorsal NT at the levels of pre-migratory (left panels), delaminating
872 (delineated in red; middle panels) and early-migrating (delineated in green; right panels) NCCs. ec,
873 ectoderm, nt, neural tube. (C) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m.) measured by
874 qRT-PCR of *SNAT-2*, *GLS*, *GDH*, and *GLUL*, in cultured NT explants with quiescent (yellow) and OXPPOS
875 (blue) profiles (left) and in NTs collected from the trunk region of HH12-13 (red) and HH14 (green)
876 embryos (right). (D) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m.) measured by qRT-PCR
877 of *Snail-2*, *Foxd-3* and *Sox-10* in the trunk of embryos 5 h after DON or vehicle (no-drug) injection. (E)
878 Whole mount views of embryos 24 h after DON or vehicle injection at HH12 hybridized with probes for
879 *Sox-10*. For each condition, an overall view of the embryo is shown on the left (red bar = 250 μ m) and a
880 detailed view of the trunk region is shown on the right (red bar = 500 μ m). Vertical bars delineate the
881 axial levels where NCCs are defective. Arrowheads and arrows point at delaminating and migrating
882 NCCs, respectively. L1, L2 and L3-labeled bars indicate the levels of the cross-sections shown in F. n = 10
883 for vehicle injection with 100% of non-affected embryos and n = 21 for DON injection with 90% of the
884 embryos showing apparent defects in NCC delamination and migration. nt, neural tube; so, somite. (F)
885 Cross-sections of whole-mount ISH for *Sox-10* at distinct levels (indicated in E) through the trunk of
886 embryos 24 h after DON or vehicle injection. Arrows point at NCCs. dm, dermamyotome; ec, ectoderm;
887 no, notochord; nt, neural tube; sc, sclerotome; so, somite. Bar = 50 μ m. (G) Left: Phase contrast images
888 of HH12/13-14 trunk NT explants after 5 h in culture in medium containing both glucose and glutamine
889 or without glutamine. ncc, neural crest cells; nt, neural tube. Bar = 100 μ m. Right: Scatter dot plot with
890 mean \pm s.e.m. of the total number per explant of NCCs (both delaminating and migrating, visualized
891 after removing of the NT explant). (H) Left: Immunofluorescence staining for *Snail-2* (red) with Dapi
892 visualization of nuclei (blue) in HH12/13-14 trunk NT explants after 5 h in culture in medium containing
893 both glucose and glutamine or without glutamine. The NT was removed before immunostaining to
894 visualize delaminating NCCs. The boundary between delaminating and migrating NCCs is delineated with
895 a yellow line. Bar = 100 μ m. Right: Scatter dot plot of the percentage of *Snail-2*-positive NCCs (both
896 delaminating and migrating) per explant. (I) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m)

897 measured by qRT-PCR of NCC delamination and migration markers in HH12/13-14 explants cultured in
898 medium with or without glutamine (black and magenta symbols, respectively). (J, K) Incidence of the
899 lack of glutamine in the culture medium on NCC locomotion properties, as measured by video-
900 microscopy using Metamorph software: Graph of the distance covered by the NCC population over time
901 (J) and scatter dot plots of the NCC velocity (mean \pm s.e.m.) throughout the duration of the experiment
902 (K) in medium containing or not glutamine. Time 0 corresponds to the onset of recording 2-4 h after
903 initiation of culture. Each dot in K corresponds to the mean velocity measured for 20 NCCs taken at the
904 periphery of the outgrowth of a NT explant. (L) Scatter dot plot of normalized mRNAs levels (mean \pm
905 s.e.m) measured by qRT-PCR of enzymes of the glutamine pathway in NT explants cultured in medium
906 with or without glutamine. Images in panels A, B, E, F, G and H are from representative experiments. In
907 C left, I and L, (n) indicate the number of experiments, with measurements done in triplicate for each
908 gene. In C right and D, (n) indicate the number of embryos, with measurements done in triplicate for
909 each gene. In G, H, J and K, (n) indicate the number of explants analyzed. In C, I and L, data were
910 analyzed using unpaired two-tailed *t*-test. In D, data were analyzed by two-way ANOVA relative to the
911 condition of "No drug". In G, H, J and K data were analyzed using one-way ANOVA followed by Dunnett's
912 multiple comparison tests relative to the condition in medium with glutamine. ns, not significantly
913 different, $P > 0.05$.
914




Figure 4: Nekoie Marnany et al.

916 **Figure 4: Glutaminase is required for NCC delamination and migration**

917 (A) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m) measured by qRT-PCR of markers of NCC
918 delamination and migration in the trunk of embryos 5 h after CB-839 or vehicle (No-drug) injection. (B)
919 Whole mount views of the trunk region of embryos 5 h (left panels) and 24 h (right panels) after CB-839
920 or vehicle injection, hybridized with probes for *Foxd-3* and *Sox-10*, respectively. For each condition, an
921 overall view of the embryo is shown on the left (red bar = 250 μ m) and a detailed view of the trunk
922 region is shown on the right (red bar = 500 μ m). Vertical bars delineate the axial levels where NCCs are
923 defective. Arrowheads and arrows point at delaminating and migrating NCCs, respectively. L1 and L2-
924 labeled bars indicate the levels of the cross-sections shown in C. n = 10 and 11 for vehicle injection with
925 100% normal embryos at 5 h and 24 h, respectively; and n = 7 and 11 for CB-839 injection with 71% and
926 73% of the embryos showing apparent defects in NCC delamination and migration at 5 h and 24 h,
927 respectively. nt, neural tube; pm, unsegmented paraxial mesoderm; so, somite. (C) Cross-sections of
928 whole-mount ISH for *Sox-10* at different levels (indicated in B) through the trunk of embryos 24 h after
929 CB-839 or vehicle injection. Arrows point at NCCs. dm, dermamyotome; ec, ectoderm; nt, neural tube;
930 sc, sclerotome; so, somite. Bar = 50 μ m. (D) Scatter dot plots of the total number of NCCs (left) and of
931 the percentage of Snail-2-positive NCCs (right) per explant (mean \pm s.e.m.) in the presence or not of CB-
932 839 during 5 hours. (E) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m) measured by qRT-
933 PCR of *GLS* (left) and markers of NCC delamination and migration (right) in the trunk of embryos 5 h
934 after injection of control siRNAs or of siRNAs to *GLS*. (F) Whole mount views of embryos 24 h after
935 injection of control siRNAs or of siRNAs to *GLS* and hybridized with probes for *Sox-10*. For each
936 condition, an overall view of the embryo is shown on the left (red bar = 250 μ m) and a detailed view of
937 the trunk region is shown on the right (red bar = 500 μ m). Vertical bars delineate the axial levels where
938 NCC development is defective. L1, L2, L3 and L4-labeled bars indicate the levels of the cross-sections
939 shown in G. Arrowheads and arrows point at delaminating and migrating NCCs, respectively. n = 11 for
940 injection of control siRNAs with 100% of non-affected embryos and n = 17 for injection of siRNAs to *GLS*
941 with 88% of the embryos showing apparent defects in NCC delamination and migration. nt, neural tube;
942 so, somite. (G) Cross-sections of whole-mount ISH for *Sox-10* at distinct levels (indicated in F) through
943 the trunk of embryos 24 h after injection of control siRNAs or of siRNAs against *GLS*. Arrows point at
944 NCCs. dm, dermamyotome; ec, ectoderm; no, notochord; nt, neural tube; sc, sclerotome; so, somite. Bar
945 = 50 μ m. Images in panels B, C, F and G are from representative experiments. In A and E, (n) indicate the
946 number of embryos with the measurements done in triplicates for each gene and in D, (n) indicate the
947 number of explants analyzed. In A and E, data were analyzed by two-way ANOVA relative to the no drug

948 condition. In D, data were analyzed using one-way ANOVA followed by Dunnett's multiple comparison
949 tests relative to the no drug condition. ns, not significantly different, $P > 0.05$.

950





Figure 5: Nekoie Marnany et al.

952 **Figure 5: Glutaminase exhibits a non-canonical function during NCC delamination**

953 (A) Effect of CB-839 (50 μ M) on OCR and ECAR in individual trunk NT explants at the delamination
954 (yellow; top) and migration (blue; bottom) stages. (B, C) Scatter dot plots of normalized mRNAs levels
955 (mean \pm s.e.m) measured by qRT-PCR of NCC delamination and migration markers (B) and players of the
956 glutamine pathway (C) in trunk NT explants at the delamination (top) and migration (bottom) stages, in
957 CB-839 (50 μ M) or vehicle (No drug). (D) Scatter dot plot of ATP levels (mean \pm s.e.m.) in explants at the
958 delamination (yellow symbols) and migration (blue symbols) stages in CB-839 (50 μ M) or vehicle (No
959 drug). In A, OCR and ECAR were recorded in individual explants before and after inhibitor treatment and
960 in B-D, mRNAs and ATP levels were measured after two additional hours in the presence of the inhibitor.
961 (E) Scatter dot plots of the intracellular concentrations (mean \pm s.e.m.) of glutamine and glutamate in NT
962 explants at the delamination and migration stages. (F) Scatter dot plots of intracellular glutamate
963 concentration (mean \pm s.e.m.) in explants at the delamination and migration stages, in CB-839 (50 μ M)
964 or vehicle (No drug). (G) Scatter dot plots of the total number of NCCs (left) and of the percentage of
965 Snail-2-positive NCCs (right) per explant (mean \pm s.e.m.) after 5 h of NT explants cultured in medium
966 containing either glucose and glutamine or in glucose and glutamate. (H) Scatter dot plot of normalized
967 mRNAs levels (mean \pm s.e.m) measured by qRT-PCR of NCC delamination and migration markers in NT
968 explants with quiescent (left) and OXPHOS (right) profiles, in the presence of glutamine or glutamate in
969 the culture medium. (I) Whole mount views of embryos 24 h after injection of glutamate (10 μ M) with
970 control siRNAs or siRNAs (28 ng/ μ l) to GLS and hybridized with probes for *Sox-10*. Detailed views of the
971 trunk region are shown (red bar = 500 μ m). The vertical bar delineates the axial levels where NCC
972 development is defective. Arrowheads and arrows point at delaminating and migrating NCCs,
973 respectively. n = 8 for injection of glutamate with control siRNAs with 100% of non-affected embryos
974 and n = 8 for injection of siRNAs to GLS with 75% of the embryos showing apparent defects in NCC
975 delamination and migration. nt, neural tube; so, somite. (J-L) Metabolic parameters (mean \pm s.e.m.) of
976 NT explants cultured in medium containing glucose and glutamate including OCR and ECAR (J), the
977 OCR/ECAR ratio (K) and ATP levels (L). (M) Scatter dot plot of normalized mRNAs levels (mean \pm s.e.m)
978 measured by qRT-PCR of enzymes of the glutamine pathway in NT explants with a quiescent (left) and
979 an OXPHOS (right) profile, in the presence of glutamine or glutamate in the culture medium. Images in I
980 are from representative experiments. In A, C, I and M, (n) indicate the number of experiments with
981 measurements done in triplicate for each gene and in B, D-G, and J-L, (n) indicate the number of
982 explants analyzed. Data were analyzed by two-way ANOVA relative to the condition with no drug or with
983 glutamine. ns, not significantly different, P > 0.05.



985 **Figure 6: Glutaminase translocates to the nucleus in delaminating NCCs**

986 (A) Immunofluorescence staining for GLS (green) with Dapi visualization of nuclei (blue) in delaminating
987 and migrating NCCs after 5 h in culture in control medium with glucose and glutamine (left) and in
988 medium containing 50 μ M CB-839 (right). Yellow arrowheads point at GLS accumulation in nuclei of
989 delaminating NCCs and yellow arrows point at nuclei in migrating cells. Bar = 20 μ m. (B) Scatter dot plots
990 of the percentage of NCCs with nuclear GLS (mean \pm s.e.m.) among the delaminating and migrating
991 populations in the indicated experimental conditions. CB-839 was applied at 50 μ M and glutamate at 10
992 μ M. (C) Horizontal confocal z-projection view of the dorsal part of the NT in the brachial region of a
993 whole mount embryo at the time of NCC delamination (left panel) and early migration (right panel),
994 immunolabeled for GLS (green) and Sox-10 (red) and stained with Dapi (blue); anterior is to the right.
995 Arrowheads point at delaminating NCCs situated along the NT midline and showing nuclear staining for
996 GLS and arrows point at migrating NCCs situated more laterally and showing nuclear staining for Sox-10
997 but not for GLS. The lateral margins of the NT are delineated with yellow lines. Bar = 50 μ m. (n = 3). (D)
998 Confocal sections through the NT in cross-sections at the level of NCC delamination (delineated with a
999 yellow line; left) and of NCC migration (delineated with a red line; right) immunolabeled for GLS (green)
1000 and stained with Dapi (blue). Insets show detail of delaminating (left) or migrating (right) NCCs in the
1001 dorsal NT. Arrowheads point at the nuclei of delaminating NCCs and arrows point at the nuclei of
1002 migrating NCCs. ec, ectoderm; nt, neural tube. Bar = 50 μ m and 10 μ m in insets. (n = 3). (E) Confocal
1003 sections through the NT in cross sections at the level of NCC delamination immunolabeled for GLS
1004 (green) and stained with Dapi (blue): left panels, embryos treated for 5 h with control siRNAs at 28
1005 ng/ μ l; right panels, embryos treated for 5 h with siRNAs (28 ng/ μ l) against GLS. Insets show detail of
1006 delaminating NCCs in the dorsal NT. Arrowheads point at the nuclei of delaminating NCCs. ec, ectoderm;
1007 nt, neural tube. Bar = 50 μ m and 10 μ m in insets. ec, ectoderm; nt, neural tube. Bar = 50 μ m. Images in A
1008 and C-E are from representative experiments. In B, (n) indicate the number of explants analyzed. Scatter
1009 plots were analyzed using one-way ANOVA followed by Dunnett's multiple comparison tests relative to
1010 the control condition in medium with glucose and glutamine without drug. ns, not significantly different,
1011 P>0.05.

1012




Figure 7: Nekooie Marnany et al.

1014 **Figure 7: Glutaminase cooperates with Wnt signaling to control NCC delamination**

1015 (A) Immunofluorescence staining for β -catenin (green) and GLS (red) with Dapi visualization of nuclei
1016 (blue) in delaminating (left) and migrating (right) NCCs after 5 h in culture in control medium containing
1017 glucose and glutamine (top) and in the presence of 50 μ M CB-839 (bottom). Arrowheads point at β -
1018 catenin and GLS accumulation in nuclei of delaminating NCCs and arrows point at β -catenin
1019 accumulation in cell-cell contacts of migrating NCCs. Bar = 20 μ m. (B) Scatter dot plots of the percentage
1020 of NCCs with nuclear β -catenin (mean \pm s.e.m.) among the delaminating and migrating populations in
1021 the presence or absence of 50 μ M CB-839. (C) Confocal images of cross sections through the NT at the
1022 level of NCC delamination immunolabeled for β -catenin (red) and GLS (green) and stained with Dapi
1023 (blue): top panels, embryos treated for 5 h with control siRNAs (n = 3); bottom panels, embryos treated
1024 for 5 h with siRNAs against GLS (n = 3). Insets show detail of delaminating NCCs in the dorsal NT.
1025 Arrowheads point at the nuclei of delaminating NCCs. β -catenin pattern is diffuse in the NCC cytoplasm
1026 and nuclei coincident with GLS nuclear accumulation in delaminating cells and it is concentrated in cell-
1027 cell contacts and absent from the nuclei after siRNAs to GLS treatment. ec, ectoderm; nt, neural tube.
1028 Bar = 50 μ m and 10 μ m in insets. (D) Confocal z-projection views of delaminating (left) and migrating
1029 (right) NCCs cultured for 5 h and immunolabeled for β -catenin and GLS followed by PLA treatment (red
1030 puncta) and staining with Dapi (blue). Insets show control PLA treatment with GLS antibodies and a non-
1031 immune mouse antibody. Bars = 10 μ m. (E) Scatter dot plots of the number of nuclear PLA puncta per
1032 NCC (mean \pm s.e.m.) among the delaminating and migrating populations in the presence or absence of
1033 CB-839. (F, G) Scatter dot plot of mRNAs (normalized levels \pm s.e.m.) measured by qRT-PCR of Cyclin-E in
1034 NT explants at the delamination (yellow) and migration (blue) stages (F) and upon different
1035 experimental conditions (G). (H) Scatter dot plot of the percentage of NCCs (both delaminating and
1036 migrating) in the S phase (mean \pm s.e.m.) in NT explants cultured in the indicated experimental
1037 conditions. Images in A, C, and D are from representative experiments. In B, E, and H, (n) indicate the
1038 number of explants analyzed, and in F and G, (n) indicate the number of experiments with the
1039 measurements done in triplicates for each gene. In B, E, and H, data were analyzed using one-way
1040 ANOVA followed by Dunnett's multiple comparison test relative to the no drug condition. In F and G,
1041 data were analyzed by two-way ANOVA relative to the quiescent profile (F) and to no drug condition (G).
1042 ns, not significantly different, P>0.05.

1043




Figure 8: Nekooie Marnany et al.

1044

1045

1046 **Figure 8: NCC cellular metabolism is coupled to developmental program**

1047 Model depicting the roles of the glucose and glutamine metabolic pathways in the control of NCC
 1048 delamination and migration. Metabolic activity evolves during delamination and migration, from
 1049 quiescence with reduced production of energy to active mitochondrial respiration for efficient energy
 1050 production. This shift results in part from a change in glucose utilization from anabolism to active
 1051 bioenergetics and, more importantly, in the function of GLS, a key enzyme of glutamine metabolism.
 1052 During delamination, GLS is preferentially translocated into the nucleus under the control of glutamine
 1053 where it associates with β -catenin (red dots in top panels), a key player of the Wnt signaling pathway.
 1054 Alternatively, GLS and β -catenin associate in the cytoplasm and are translocated together into the
 1055 nuclei. Nuclear GLS and β -catenin would participate in the control of expression of key genes, such as
 1056 *Snail-2*, *Foxd-3* and *Cyclin-E*, to regulate EMT and cell-cycle progression, two necessary events of the
 1057 delamination process. Once delamination is complete, GLS is no longer present in the nucleus and
 1058 instead it displays its classical enzymatic activity in mitochondria to convert glutamine into glutamate, to

1059 contribute to ATP production together with glucose to promote NCC migration. Coincidentally, β -catenin
1060 is excluded from the nucleus and is preferentially targeted to cell-cell junctions.

1061


1062 **EXTENDED DATA FIGURES**

1063 **Extended data Figure 1:**

1064 **Extended data Figure 2, related to Fig. 3:**

1065

1066




Supplementary figure 1: Nekooie-Marnany et al.

1068 **Extended data Figure 1:**

1069 (A) Expression patterns of markers for NCC delamination and migration at stages HH12-13 (left) and
1070 HH14-15 (right). Whole mount views of the thoracic region at mid-trunk level (corresponding to somite
1071 pairs 15-22) of quail embryos hybridized with probes for *Cadherin-6B*, *Snail-2*, *Foxd-3*, and *Sox-10*. The
1072 diagrams depict the gross morphology of the embryos at the respective stages, and the regions shown in
1073 the in situ hybridization images are delineated by red rectangles. In situ hybridizations for each probe
1074 and at each developmental stage were done in triplicate. Bar = 500 μ m. nt, neural tube; pm, presomitic
1075 paraxial mesoderm; so, somite. (B) Schematic representation of the procedure for analyzing *in vitro* the
1076 metabolic profile of individual NT explants at stages HH12/13 to HH14 and the corresponding molecular
1077 and cellular properties of NCCs (see Methods for details of the procedure). The embryonic region
1078 extirpated for NT dissection is delineated with a red rectangle. (C) Schematic representation of the
1079 procedure to characterize the molecular features of NTs and associated NCCs collected from embryos at
1080 stages HH12-13 and HH14. The embryonic region extirpated for mRNA extraction is delineated with a
1081 red rectangle. (D) Schematic representation of the procedure for *in-ovo* injection of quail embryos for
1082 loss-of-function studies with indication of the timing of NCC development (see Methods for details of
1083 the procedure). In C and D, zones with NCC at the delamination and migration stage are colored in red
1084 and green, respectively. Images in A are from representative experiments.

1085

1086



Supplementary figure 2: Nekooie-Marnany et al.

1087

1088 **Extended data Figure 2, related to Fig. 3:**

1089 (A-E) NT explants cultured in medium lacking glutamine (magenta symbols) were analysed for metabolic
1090 parameters (mean values \pm s.e.m.) including OCR and ECAR (A); the OCR/ECAR ratio (B); basal, minimal,
1091 and maximal OCR (C); coupling efficiency (left) and spare respiratory capacity (right) (D); and ATP levels
1092 (E). n indicates the number of explants analyzed.

1093